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AbstrACt
Objective To assess the incidence of hip fracture and 
all major osteoporotic fractures (MOF) in patients with 
chronic obstructive pulmonary disease (COPD) compared 
with non-COPD patients and to evaluate the use and 
performance of fracture risk prediction tools in patients 
with COPD. To assess the prevalence and incidence of 
osteoporosis.
Design Population-based cohort study.
setting UK General Practice health records from The 
Health Improvement Network database.
Participants Patients with an incident COPD diagnosis 
from 2004 to 2015 and non-COPD patients matched by 
age, sex and general practice were studied.
Outcomes Incidence of fracture (hip alone and all MOF); 
accuracy of fracture risk prediction tools in COPD; and 
prevalence and incidence of coded osteoporosis.
Methods Cox proportional hazards models were used to 
assess the incidence rates of osteoporosis, hip fracture 
and MOF (hip, proximal humerus, forearm and clinical 
vertebral fractures). The discriminatory accuracies (area 
under the receiver operating characteristic [ROC] curve) of 
fracture risk prediction tools (FRAX and QFracture) in COPD 
were assessed.
results Patients with COPD (n=80 874) were at an 
increased risk of fracture (both hip alone and all MOF) 
compared with non-COPD patients (n=308 999), but 
this was largely mediated through oral corticosteroid 
use, body mass index and smoking. Retrospectively 
calculated ROC values for MOF in COPD were as follows: 
FRAX: 71.4% (95% CI 70.6% to 72.2%), QFracture: 
61.4% (95% CI 60.5% to 62.3%) and for hip fracture 
alone, both 76.1% (95% CI 74.9% to 77.2%). Prevalence 
of coded osteoporosis was greater for patients (5.7%) 
compared with non-COPD patients (3.9%), p<0.001. The 
incidence of osteoporosis was increased in patients with 
COPD (n=73 084) compared with non-COPD patients 
(n=264 544) (adjusted hazard ratio, 1.13, 95% CI 1.05 to 
1.22).
Conclusion Patients with COPD are at an increased risk 
of fractures and osteoporosis. Despite this, there is no 
systematic assessment of fracture risk in clinical practice. 
Fracture risk tools identify those at high risk of fracture in 
patients with COPD.
IntrODuCtIOn  
Osteoporosis in both male and female 
patients with chronic obstructive pulmonary 
disease (COPD) is firmly established as one 
of the core comorbid conditions.1 2 Over the 
last decade, it has become clear that osteopo-
rosis is not just an end-stage COPD problem3 
nor just in those on maintenance oral corti-
costeroids (OCS), but it also occurs in a large 
proportion of those with mild–moderate 
airflow obstruction and even in steroid naïve 
patients.4 5 The Global Initiative for COPD 
(GOLD) strategy recommends that osteo-
porosis co-existence should be considered 
in COPD,1 and that the UK National Insti-
tute for Health and Care Excellence (NICE) 
Guidelines on osteoporosis considers COPD 
as a secondary cause of osteoporosis encour-
aging the use of fracture prediction tools.6 
The causes for osteoporosis in COPD are 
likely multiple and cumulative, including age, 
smoking exposure, inactivity, low body mass 
index (BMI), systemic inflammation and the 
strengths and limitations of this study
 ► This study examined electronic health records from 
a large, nationally representative sample of the UK 
population.
 ► A wide range of potential confounders were evaluat-
ed and adjusted for in the analyses.
 ► For the assessment of the fracture prediction tools, 
the population of patients with COPD used was 
large, with many fracture (hip alone and all MOF) 
events, and it included both men and women.
 ► READ codes recorded in UK primary care do not 
capture free text from consultations but capture new 
diagnoses, such as diagnosed osteoporosis, and 
significant fractures, such as those classed as MOF.
 ► The incidence of diagnosed osteoporosis based on 
clinical codes may reflect an underestimation of the 
true risk of osteoporosis since bone mineral density 
is not systematically assessed.
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frequent use of OCS.7 The clinical implications of osteo-
porosis include increased risk of fractures, poor quality 
of life, pain and further deterioration in lung function.8 9 
Osteoporosis can also remain undiagnosed as asymptom-
atic for many years.10 Fractures are a function of trauma 
sustained, such as falls which are common in COPD,11 and 
affect the quality and architecture of the bone. Fractures 
contribute further pain, poor quality of life, increased 
mortality and confer a substantial economic burden on 
health systems, patients and their families.12 13 Given this, 
the individual risk of a future fracture in patients with 
COPD is crucial to determine in-patient care and to treat 
accordingly.
Fracture risk prediction tools based on clinical and 
personal characteristics have been developed over the 
years to guide the investigation and management of those 
identified to be at high risk of osteoporotic fractures, 
worldwide. These include for the UK (and many other 
regions), FRAX and QFracture.6
The full extent of fracture risk assessment in patients 
with COPD is not fully established. The aim of this study 
was to assess the incidence of hip fracture alone or all 
major osteoporotic fractures (MOF) in patients with 
COPD compared with non-COPD patients, and to eval-
uate the use and performance of fracture risk predic-
tion tools in patients. Further, to assess the prevalence of 
coded osteoporosis up to the time of COPD diagnosis and 
the incidence of osteoporosis.
MethODs
Information for this cohort study was obtained from The 
Health Improvement Network (THIN), an anonymised 
primary care database representing 6.2% of the total UK 
population.14
The study population consisted of patients 40 years and 
over with a new READ-coded COPD diagnosis during the 
data collection period 1st January 2004 to 31st December 
2015, with at least 1 year of record prior to COPD diag-
nosis.15 Each patient was matched by age, sex and general 
practice (GP) to up to four patients without a history of 
COPD to generate a matched cohort and assigned the 
same index date.
Follow-up was from the index date to the first record 
of either the occurrence of the outcome of interest (frac-
ture/osteoporosis), the date of transfer of the patient out 
of the practice area, death or the end of THIN data collec-
tion. Diagnoses for osteoporosis—classed as coded osteo-
porosis (online appendix 1), hip fracture alone and all 
MOF (comprising fracture of the hip, proximal humerus, 
forearm or clinically symptomatic vertebra/spine), coded 
using the standard READ code classification were used.16
A series of explanatory variables6 17 determined at base-
line (prior to or at index date) included Charlson Comor-
bidity Index (CCI) score,18 Townsend social deprivation 
score, recorded history of fall, prior fractures, parental 
history of fall/osteoporosis, relevant comorbidities and 
secondary causes of osteoporosis as defined in the FRAX 
questionnaire.19 Records for smoking status, alcohol use, 
Medical Research Council (MRC) Dyspnoea scale, BMI 
and use of specific prescription drugs were restricted to a 
defined time period.
To account for the use of OCS, individual follow-up time 
was divided into periods during which participants were 
considered exposed, or not exposed, to OCS (a binary 
variable). Exposed periods started from prescription date 
until the first gap of more than 90 days between prescrip-
tions, with individuals considered unexposed from the 
91st day onwards. Individuals were considered exposed 
at study entry if they had received a relevant prescription 
within 90 days prior. The effect of exposure was assumed 
to be constant, and not cumulative, over time.
Input variables included clinical status, prescription 
drug use, and demographic characteristics, according to 
the variables/definitions used in both FRAX and QFrac-
ture tools,19 20 additional detail on the method is provided 
in an online data supplement (online appendix 2). Impu-
tation was used for missing variables.
The 10-year risk score for hip fracture alone and all 
MOF according to QFracture (V.2017.0.0.0) and FRAX 
for UK (without bone mineral density [BMD] informa-
tion) (desktop V.3.12) were calculated for patients with 
COPD, aged 40–90 years. A complete case sensitivity anal-
ysis without imputed variables was also performed (online 
appendix 3).
statistical analyses
Incidence rates were calculated for both groups using 
Cox proportional hazards regression to estimate HRs of 
coded osteoporosis and fracture (hip alone and all MOF) 
risks. Conditional analysis to account for matching by 
age, sex and GP practice was done. Confounders were 
included in the final fully adjusted multivariable models 
when independently changing the HRs for osteoporosis/
fracture by at least 5%. A former osteoporosis diagnosis 
or antiresorptive treatment prior to COPD diagnosis 
excluded that subject from analyses related to either 
osteoporosis incidence or risk (online appendix 4). In 
addition to evaluating incidence in the whole cohort, 
separate sub-analyses excluded (a) patients with COPD 
and no documented smoking history together with their 
matched non-COPD patients and (b) those with no prior 
record of osteoporosis.
To evaluate FRAX and QFracture, the outcome was 
treated as a binary variable (fracture or no fracture). Frac-
ture risk probabilities were categorised based on recom-
mended treatment thresholds (≥20% for MOF and ≥3% 
for hip fracture).21 To evaluate the overall ability of each 
tool to discriminate (performance) between those at low 
and high risks, the area under the receiver operating 
characteristic (ROC) curve was calculated. Sensitivity, 
specificity, and positive and negative predictive values 
were calculated. Survival analysis was performed and 
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All statistical analyses were performed using Stata 15.0 
(StataCorp LP).
Patient involvement
The results and implications of previous research from 
the team on the systematic assessment of osteoporosis in 
patients with COPD4 have been discussed extensively in 
previous patient meetings. While this and other literature 
have strengthened the GOLD strategy recommendations,1 
evaluation of clinical services would suggest systematic 
assessment is not done in patients. More recently, patients 
with COPD out-patient clinics have approached the prin-
cipal investigator at the time of their ‘ad hoc osteoporosis’ 
diagnosis to ask why this was not investigated at or closer to 
COPD diagnosis and how osteoporosis could be assessed. 
This has led to the development of this grant application 
with significant patient input in the design and context. 
The results have been discussed back with representatives 
on the respiratory research panel. Given the implications 
for clinical practice, the findings have been discussed 
extensively at the patient and public involvement meeting 
and a Breathe Easy meeting in early 2018. A lay summary 
has been developed for the patient newsletter (n>700) 
and website. In the meantime, members of the respira-
tory research panel are assisting the PI in planning future 
work regarding implementation.
results
The baseline characteristics are shown in table 1. A 
total of 80 874 eligible patients with COPD and 308 999 
matched non-COPD patients were identified. The median 
follow-up period was 5 years for both patients with COPD 
and non-COPD patients.
Osteoporosis at index date and incidence
The prevalence of coded osteoporosis up to the index 
date was greater for patients with COPD (5.7%) 
compared with non-COPD patients (3.9%), p<0.001. 
Within 1 year (before and after) of the index date, 1504 
(1.86%) patients with COPD had a new recorded diag-
nosis of osteoporosis compared with 3059 (1.12%) in 
matched non-COPD patients, p<0.001. Three thousand 
one hundred and eighty-six (3.94%) patients with COPD 
had a diagnosis of osteoporosis more than a year prior to 
index date compared with 8822 (2.86%) for the matched 
controls, p<0.001.
One thousand four hundred and fifty-seven (1.80%) 
patients with COPD compared with 3694 (1.20%) 
non-COPD patients had a record of any diagnostic assess-
ment for osteoporosis, recorded within 1 year (before and 
after) of the index date, p<0.001.
Demographics remained similar after excluding 
those with former coded osteoporosis. Patients with 
COPD (n=73 084) compared with non-COPD patients 
(n=2 64 544) were significantly more likely to have an inci-
dent diagnosis of osteoporosis (HR, 1.96; 95% CI 1.87 to 
2.05; online appendix 5).
Incidence of fracture
There was a significantly increased risk of MOF, 
HR of 1.60 (95% CI 1.52 to 1.69) and hip fractures 
alone: 1.67 (95% CI 1.56 to 1.80) in patients with 
COPD compared with non-COPD patients. In the fully 
adjusted models, the associations were diminished 
(table 2). Smoking status altered the effect between 
COPD and fracture the most, followed by BMI, CCI 
score and OCS.
Sensitivity analysis with participants with no former 
osteoporosis showed similar results. The risk of MOF 
was also similar when evaluated in patients only with 
COPD with a documented prior history of smoking 
and their matched controls. However, here, the risk 
of hip fracture remained significantly increased in the 
adjusted model compared with non-COPD patients 
(aHR, 1.13; 95% CI 1.004 to 1.280; p-value: 0.043).
Fracture risk prediction tools in COPD
Only 1074 (1.33%) of the patients with COPD had a 
FRAX assessment READ-coded ever documented in the 
records and 12 patients had a READ coded QFracture 
assessment. Within 1 year (before and after) of index 
date, 248 (0.31%) of the patients with COPD had a FRAX 
and only one patient a QFracture.
The final population for the discriminatory accuracy 
analysis comprised 72 559 patients aged 40–90 years with 
COPD and no prior diagnosis of osteoporosis or prescrip-
tion of any anti-resorptive treatment (demographics in 
onlineappendix 6). This included 4605 (6.4%) patients 
who experienced any MOF and 1444 (2.0%) who experi-
enced a hip fracture.
When the FRAX and QFracture scores were calculated 
for patients with COPD, for hip fracture there were 
29 035 (40.0%) patients who had a risk≥3% using FRAX 
and 33 065 (45.6%) patients using QFracture. For any 
MOF, 6221 (8.6%) of the patients had a risk≥20% using 
FRAX and 9546 (13.2%) patients using QFracture.
Both risk tools had a similar discriminatory accuracy 
for hip fracture (FRAX 76.1%, 95% CI 74.9% to 77.2% 
and QFracture 76.1%, 95% CI 74.9% to 77.2%). FRAX, 
however, had a higher accuracy for MOF (71.4%–95% CI 
70.6% to 72.2%) than QFracture (61.4%–95% CI 60.5% 
to 62.3%). The discriminatory accuracies were better in 
women than men. The performance of the prediction 
tools was similar in patients aged 50–90 years compared 
with those aged 40–90 years.
The sensitivity of the risk scores for any MOF 
(using >20% risk as cut-off) was similar: FRAX: 25.4% 
and QFracture: 25.2%. The sensitivity of the risk scores 
for hip fracture (using >3% cut-off) was slightly worse for 
FRAX: 78.1% compared with 82.1% for QFracture. The 
specificity and positive predictive value were better for 
FRAX than QFracture, table 3.
The association of an increased fracture risk (either 
FRAX or QFracture) with the incidence of any MOF is 
shown in figure 1.
 o
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DIsCussIOn
Using UK primary care electronic health records, we 
have reported on the burden of fractures in patients with 
COPD with both hip fracture alone or any MOF increased 
in patients with COPD compared with age, sex and GP 
surgery matched patients. Despite the increased fracture 
risk and recommendations in the NICE osteoporosis 
guidelines, fracture risk prediction tools are rarely coded. 
However, where the risk score was retrospectively calcu-
lated, the risk prediction tools identify those at risk of hip 
fracture or any MOF. Therefore, fracture risk prediction 
and subsequent targeted therapy and management could 
transform multi-morbidity management of COPD. In 
addition, we report that the prevalence and incidence of 
osteoporosis, a risk for fracture, in patients with COPD, is 
far greater than in non-COPD patients.
Table 1 Baseline characteristics of patients with COPD and non-COPD patients
Descriptor
COPD patients Non-COPD patients
P valuen=80 874 % n=308 999 %
Mean age at index date (years, SD) 66.9 (11.0) 66.5 (10.9)
Sex 0.002
  Male 42 799 52.9 161 648 52.3
  Female 38 075 47.1 147 351 47.7
Follow-up (years, median, IQR) 5.28 2.6–8.3 5.24 2.6–8.3
MRC Dyspnoea Scale (1 year either side of 
diagnosis)
<0.001
  1 9499 11.8 1168 0.4
  2 19 466 24.1 1092 0.4
  3 10 488 13.0 446 0.1
  4 & 5 5237 6.5 177 0.1
  No record 36 184 44.7 306 116 99.1
CCI score <0.001
  0 0 0.0 172 566 55.9
  1 41 777 51.7 50 955 16.5
  2 13 506 16.7 42 667 13.8
  3 12 694 15.7 23 546 7.6
  ≥4 12 897 16.0 19 265 6.2
BMI (kg/m2) <0.001
  Underweight (<18.5) 3414 4.2 2699 0.9
  Normal (18.5–24.9) 24 734 30.6 54 267 17.6
  Overweight (25–29.9) 23 497 29.1 77 129 25.0
  Obese (≥30) 19 083 23.6 60 280 19.5
  No BMI 10 146 12.6 114 624 37.1
Smoking status (1 year either side of diagnosis) <0.001
  Never smoked 7925 9.8 94 800 30.7
  Ex-smoker 38 590 47.7 72 989 23.6
  Current smoker 32 436 40.1 34 691 11.2
  Unknown 1923 2.4 106 519 34.5
History of falls (prior to or at diagnosis)
  Personal history 8969 11.1 26 203 8.5 <0.001
  Parental history of fall/osteoporosis 96 0.1 298 0.1 0.076
Medications (1 year either side of diagnosis)
  OCS use 33 618 41.6 19 479 6.3 <0.001
  Inhaled corticosteroid use 47 574 58.8 21 312 6.9 <0.001
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Prevalence of osteoporosis varies widely in the different 
research studies of patients with COPD. This is likely due to 
the severity of COPD,4 5 whether osteoporosis was system-
atically sought or self-reported,4 22 and whether patients 
included were on OCS.3 A prevalence of 23%–32% has 
been reported where BMD was systematically performed 
in COPD,4 23 while 14% of the patients with COPD self-re-
ported osteoporosis compared with 5% in those without 
COPD.22 The prevalence of coded osteoporosis in the GP 
health records presented here was, however, far lower at 
5.7% than the reported prevalence from clinical studies 
when osteoporosis and BMD are systematically assessed. 
This raises the question of subclinical, undiagnosed oste-
oporosis leading to a missed opportunity for intervention 
and strengthening the need for a systematic assessment, 
especially when cost-efficient anti-resorptive treatment is 
available.24
There is growing consensus on COPD being a 
secondary cause of osteoporosis, including within the 
NICE clinical guidelines on osteoporosis where fracture 
risk prediction tools are recommended, yet in practice 
seem rarely done.6While osteoporosis in itself leads to 
pain and poor quality of life,25 ultimately osteoporosis 
treatment aims to reduce the risk of fracture.24 26 Risk 
factors for fracture include osteoporosis but also falls, 
which, are greater in patients with COPD.11 27 While the 
increased risk of fractures in COPD has previously been 
considered,28 they have not assessed the incidence from 
the time of COPD diagnosis or only reported as part of 
a larger study of post-menopausal women29 or analysed 
the history of obstructive airway disease (COPD and 
asthma together) before the index date of osteoporotic 
fracture in both cases and controls over the age of 18 
years.30







Fully adjusted HR 
(95% CI)
MOF
  Non-COPD patients 6032 4.32 (4.22–4.44) Reference Reference
  Patients with COPD 2234 6.64 (6.37–6.92) 1.60 (1.52 to 1.69) 1.04 (0.96 to 1.12)*
Hip fracture
  Non-COPD patients 3170 2.26 (2.18–2.34) Reference Reference
  Patients with COPD 1213 3.57 (3.38–3.78) 1.67 (1.56 to 1.80) 1.09 (0.98 to 1.21)†
Fully adjusted:
*Multivariable Cox regression model-derived HR was adjusted for age, sex, GP, CC I, BMI, smoking status, inhaled corticosteroid use, 
antidepressant use and cumulative OCS use.
†Multivariable Cox regression model-derived HR was adjusted for age, sex, GP, CCI, BMI, smoking status, inhaled corticosteroid use and 
cumulative OCS use.
BMI, body mass index; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; GP, general practice; MOF, major 
osteoporotic fractures; OCS, oral corticosteroid; HR, conditional regression used to account for matching by age, sex and GP.









  Sensitivity 25.4% (22.7% to 28.1%) 25.2% (22.5% to 27.9%)
  Specificity 92.6% (91.0% to 94.2%) 87.7% (85.7% to 89.7%)
  Positive predictive value 18.8% (16.4% to 21.1%) 12.2% (10.2% to 14.2%)
  Negative predictive value 94.8% (93.4% to 96.2%) 94.5% (93.1% to 95.9%)
Measure for ≥3% risk Measure for ≥3% risk
Hip fracture
  Sensitivity 78.1% (75.6% to 80.7%) 82.1% (79.7% to 84.5%)
  Specificity 60.8% (57.8% to 63.8%) 55.2% (52.1% to 58.3%)
  Positive predictive value 3.9% (2.7% to 5.1%) 3.6% (2.5% to 4.8%)
  Negative predictive value 99.3% (98.8% to 99.8%) 99.3% (98.8% to 99.8%)
MOF, major osteoporotic fractures.
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Little is known about the use of fracture risk assess-
ment tools in patients with COPD. A number of valida-
tion studies have performed independent assessments 
to predict subsequent fracture in the general popula-
tion.31 32 The studies differ widely in sample size, meth-
odology, and techniques used to assess performance.33 
Discrimination for FRAX (without BMD incorporation) 
and QFracture have both been reported as good.31 34 35 
The results from this COPD study are comparable to the 
general population validation studies;31 34 35 however, the 
area under curve for MOF using QFracture was lower 
than that reported in other studies. Similar to findings 
from studies based on general population, the discrimi-
nation from our study was better in women than men and 
better for hip fracture than MOF.36 The discrimination 
appeared similar within the 50–90-year-old group when 
compared with the 40–90-year olds. Despite the two tools 
having differences in their approach to calculating frac-
ture risks, both predict fractures satisfactorily in patients 
with COPD. Despite the sensitivity and positive predic-
tive values being far from ideal, sensitivity reported in 
our study are comparable to those published in studies 
using a general population.31 35 Although a bespoke 
COPD tool could be adapted in the future, the use of one 
of the established fracture risk scores in the meantime 
provides the opportunity to systematically identify and 
intervene. Such tools are incorporated into primary care 
medical record systems and utilised in a number of other 
disease areas. The available fracture prevention therapy 
(anti-resorptive agents) are very effective, safely yielding 
40%–60% reduction in the risk of fracture.26 These medi-
cations are cost-effective in high-risk patients—reduces 
morbidity, mortality and the healthcare cost associated 
with osteoporotic fractures.24 The fracture prediction 
tools could be integrated into COPD annual assessments 
or at COPD diagnosis. The identification of patients at 
high risk is a valuable information to guide and optimise 
treatment options, though the optimal pathways for this 
integration is required.
The use of OCS has been considered to be a major 
contributory factor in the development of osteoporosis. 
However, osteoporosis has been reported in patients with 
no OCS use.4 5 Other known osteoporosis risk factors are 
also likely to contribute in patients with COPD, including 
smoking, a low BMI, physical inactivity and systemic 
inflammation. Some of these risk factors could be moder-
ated through education, smoking cessation, pulmonary 
rehabilitation and lifestyle changes.37 38 Recognition of 
the scale and impact of fracture risk draws further neces-
sary attention to these interventions to aim to prevent and 
reduce risks, alongside appropriate pharmacotherapy.
The study had several strengths in its methods, analyses, 
findings and implications for clinical practice. First, this 
research was population-based and compared patients 
with COPD with age-sex-matched control patients from 
the same GP. Its external validity and hence generalisability 
was high because the THIN database is representative of 
the UK population.14 There was a substantial duration of 
follow-up. A wide range of potential confounders were 
also evaluated and adjusted for in the analyses.
For the assessment of the fracture prediction tools, 
the population of patients with COPD used was large, 
with many fracture events, and included both men and 
women. This minimised the likelihood of a selection bias. 
The assessments of the prediction tools were done using 
the same population, therefore minimising the effect 
of confounding for a difference in performance. We 
are presently not aware of studies that have determined 
the performance of the recommended fracture predic-
tion tools in the sub-population of patients with COPD. 
The dataset was using UK electronic health records but 
is likely representative of other countries in representing 
the scale of the problem and the utility of the risk predic-
tion scores.
Regarding limitations, some variables might be subject 
to information or reporting bias as READ codes recorded 
in databases do not capture free text from consultations. 
Such variables include patient-reported alcohol intake, 
use of cigarettes or their awareness of relevant family 
history. The possibility of residual confounding can also 
not be excluded as risk factors such as physical activity, 
Figure 1 Kaplan-Meier plots comparing the incidence of 
MOF at various predicted fracture risk categories in patients 
with COPD using (A) FRAX and (B) QFracture. COPD, chronic 
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diet and ethnicity could not be adjusted for in the anal-
yses. An accepted definition of fracture types was used; 
however, it is difficult to determine the cause of fracture 
based simply on the fracture site, with no additional infor-
mation. Unlike studies which assess BMD systematically, 
this is not currently done in clinical practice, nor are the 
fracture risk scores routinely calculated as highlighted 
here. Therefore, the incidence of osteoporosis based on 
clinical codes likely reflects an underestimation of the 
true increased incidence/risk of osteoporosis.
In summary, despite validated fracture risk prediction 
tools, there was very little assessment of the increased frac-
ture risk in patients with COPD. However, on retrospec-
tive calculation of fracture risk, the tools identify those 
patients with COPD at greatest risk of fracture. The iden-
tification with a systematic assessment of bone health and 
addressing prevention and treatment of those at a greater 
risk of fracture have the potential to improve outcomes 
for patients with COPD.
twitter @Bolton_char @COPDNotts @NottmBRCLung
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